Your shopping cart is currently empty

VEGFR-2-IN-67 (Compound 6b) functions as an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), with IC50 values of 5.91 µM for MDA-231 cells and 7.16 µM for MCF-7 cells. Its inhibitory activity on VEGFR-2 is comparable to Sorafenib (IC50 of 53.63 nM). VEGFR-2-IN-67 exhibits significant anticancer activity by inducing cell apoptosis (with an early apoptosis rate of 57.20%), causing G1 phase cell cycle arrest, upregulating pro-apoptotic markers, and downregulating Bcl-2. This compound is utilized in cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | VEGFR-2-IN-67 (Compound 6b) functions as an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), with IC50 values of 5.91 µM for MDA-231 cells and 7.16 µM for MCF-7 cells. Its inhibitory activity on VEGFR-2 is comparable to Sorafenib (IC50 of 53.63 nM). VEGFR-2-IN-67 exhibits significant anticancer activity by inducing cell apoptosis (with an early apoptosis rate of 57.20%), causing G1 phase cell cycle arrest, upregulating pro-apoptotic markers, and downregulating Bcl-2. This compound is utilized in cancer research. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.